Prenetics Global (NASDAQ:PRE) Issues Earnings Results, Misses Estimates By $0.03 EPS

Prenetics Global (NASDAQ:PRE – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.03), Zacks reports. Prenetics Global had a negative return on equity of 21.41% and a negative net margin of 47.43%. The company had revenue of $64.11 million for the quarter, compared to the consensus estimate of $63.18 million.

Here are the key takeaways from Prenetics Global’s conference call:

  • Q3 revenue rose 37.9% sequentially to $64.1 million, with IM8 contributing $62.9 million; September was a record month. The company said quarterly customer acquisition costs declined for a second consecutive quarter, to about $285.
  • Management reported strong customer returns: its earliest cohort has generated $4.10 in gross profit per acquisition dollar, while the next 91,000 customers are at about $2.70 and are expected to reach 3.0 early in 2027. Repeat orders accounted for 59% of quarterly billings, and the company ended September with about 160,000 active subscriptions.
  • Prenetics raised its expected second-half adjusted EBITDA loss to $30 million–$35 million, from $8 million–$12 million previously, as it chose to increase growth spending. Q3 adjusted EBITDA loss was $12.7 million; management said Q4 spending will remain elevated if customer returns hold.
  • The company reaffirmed 2026 revenue guidance of $220 million–$230 million and its 2027 IM8 revenue target of at least $400 million, based on current products. Hydration and Care Bears products, planned for 2027, plus potential retail and China launches are excluded from that target and remain subject to execution and partnership or regulatory requirements.

Prenetics Global Price Performance

Shares of PRE stock opened at $10.35 on Thursday. Prenetics Global has a 12-month low of $9.13 and a 12-month high of $27.24. The firm has a market capitalization of $174.60 million, a price-to-earnings ratio of -2.49 and a beta of 0.40. The business has a 50 day simple moving average of $19.80 and a 200 day simple moving average of $19.48.

Insider Activity at Prenetics Global

In other Prenetics Global news, CFO Brian Rosin bought 5,100 shares of the business’s stock in a transaction on Tuesday, August 25th. The shares were purchased at an average price of $22.80 per share, with a total value of $116,280.00. Following the purchase, the chief financial officer directly owned 23,100 shares of the company’s stock, valued at approximately $526,680. The trade was a 28.33% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Danny Sheng Wu Yeung purchased 17,181 shares of Prenetics Global stock in a transaction on Monday, August 24th. The shares were acquired at an average price of $21.23 per share, with a total value of $364,752.63. Following the transaction, the chief executive officer directly owned 112,416 shares in the company, valued at $2,386,591.68. This trade represents a 18.04% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders purchased 40,281 shares of company stock worth $862,453. 7.80% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Prenetics Global in a research note on Thursday, October 15th. Wall Street Zen upgraded shares of Prenetics Global from a “sell” rating to a “hold” rating in a research report on Saturday, August 22nd. Craig Hallum initiated coverage on shares of Prenetics Global in a research report on Thursday, September 17th. They set a “buy” rating and a $40.00 price target for the company. Maxim Group began coverage on shares of Prenetics Global in a report on Monday, October 26th. They issued a “buy” rating and a $41.00 price objective on the stock. Finally, Lucid Cap Mkts upgraded shares of Prenetics Global to a “strong-buy” rating in a research report on Monday, October 12th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $37.17.

Check Out Our Latest Research Report on PRE

Trending Headlines about Prenetics Global

Investors following PRE have been watching these headlines:

  • Positive Sentiment: IM8 revenue rose 266% year over year to $62.9 million, marking its seventh consecutive record quarter. Prenetics reaffirmed full-year 2026 revenue guidance of $220–230 million and forecast IM8 revenue of more than $400 million in 2027. Prenetics IM8 Q3 results and guidance
  • Neutral Sentiment: Fourth-quarter revenue guidance of $73–83 million brackets the $78.6 million consensus estimate, while full-year revenue guidance is also broadly in line with expectations.
  • Negative Sentiment: Quarterly EPS was a loss of $1.45, substantially worse than the expected loss of $0.82. The company also raised its expected second-half adjusted EBITDA loss to $30–35 million from $8–12 million, citing increased investment in customer acquisition. These results and the higher spending outlook were reported as weighing on the shares. MarketWatch report on results and guidance

Prenetics Global Company Profile

(Get Free Report)

Prenetics Global Limited is a health sciences company focused on consumer wellness and health-related products. Its portfolio includes IM8, a consumer wellness brand offering nutritional supplements, and CircleDNA, a genetic testing service that provides reports on health, wellness and ancestry. The company has also operated clinical genomic testing services and provided COVID-19 testing during the pandemic. Its business has since shifted toward consumer health and wellness. Prenetics was founded in 2014 and is led by co-founder and Chief Executive Officer Danny Yeung.

Read More

Earnings History for Prenetics Global (NASDAQ:PRE)

Receive News & Ratings for Prenetics Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prenetics Global and related companies with MarketBeat.com's FREE daily email newsletter.